StageZero Life Sciences Ltd
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply. The addition of non-cytotoxic agents with well-established safety profiles seeks to impede the prospects of cancer cell survival, especially in a hostile environment, such as during chemotherapy, radiotherapy, immunotherapy and hormone therapy.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692888/StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Foundations of Neutrinovoltaics: From Shared Knowledge to Shared Future4.9.2025 20:08:00 CEST | Press release
Uniting Mathematics, Artificial Intelligence, and Neutrino Science into a New Energy Paradigm BERLIN, DE / ACCESS Newswire / September 4, 2025 / Every technological leap builds on decades of knowledge. Neutrinovoltaics is no exception. Its foundation lies in the convergence of three intellectual streams, mathematics, artificial intelligence, and neutrino science, that together redefine how electricity can be generated.Holger Thorsten Schubart on Shared Science Celebrating the science that powers neutrinovoltaics The governing formula formalizes this principle: P(t) = η · ∫V Φ_eff(r,t) · σ_eff(E) dV It shows in precise terms how efficiency, flux density, interaction cross-section, and material volume convert invisible radiation into usable current. What once was intangible now has calculable structure. Holger Thorsten Schubart: Visionary and Bridge-Builder At the center of this development stands Holger Thorsten Schubart, mathematician and CEO of Neutrino® Energy Group. For over a decad
LOLC Advanced Tech and Corsair Group Join Forces to Transform Waste into Fuel in Sri Lanka4.9.2025 18:50:00 CEST | Press release
AMSTERDAM, NETHERLANDS / ACCESS Newswire / September 4, 2025 / LOLC Advanced Technologies (LOLC AT), a fully owned subsidiary of LOLC Holdings PLC, together with Corsair Group International, headquartered in Amsterdam, has announced a landmark partnership to upgrade and expand LOLC AT's existing waste-to-fuel plant at Kerawalapitiya. This strategic initiative aims to address Sri Lanka's growing plastic and polythene waste challenge. With Sri Lanka generating an estimated 7,000 metric tons of solid waste per day, equating to roughly 2.56 million metric tons per year, a significant portion of which consists of polythene and plastic. Plastic pollution has become one of the nation's most pressing environmental concerns, with much of this waste ends up in overflowing landfills, waterways, and oceans, posing serious threats to ecosystems, public health, and tourism. LOLC AT invested in and commissioned a waste-to-fuel plant in 2023, which it has successfully operated throughout 2024. This fa
MicroVision Appoints Glen DeVos as Chief Executive Officer4.9.2025 15:20:00 CEST | Press release
REDMOND, WA / ACCESS Newswire / September 4, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced that the Company's Board of Directors has appointed Glen W. DeVos as Chief Executive Officer and a member of the Company's Board of Directors effective September 30, 2025. Sumit Sharma, the Company's current CEO, will remain in the role through the effective date to ensure a smooth transition. A seasoned executive, DeVos brings more than three decades of leadership in the automotive and industrial technology sectors, delivering advanced technologies and solutions with a focus on autonomy and mobility. Since 1992, DeVos served in various business leadership and technology roles at Aptiv, and its predecessor Delphi Automotive, including as Aptiv's Chief Technology Officer and President of the Advanced Safety and User Experience business unit. His extensive experience developing and driving strategy, le
U.S. Polo Assn. Celebrates Historic Title Sponsorship of 2025 Pacific Coast Open at Santa Barbara Polo & Racquet Club4.9.2025 13:00:00 CEST | Press release
Global Sports Brand Marks Eighth Year Partnering with the Iconic West Coast Polo Club SANTA BARBARA, CA AND WEST PALM BEACH, FL / ACCESS Newswire / September 4, 2025 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly marked a major milestone this past weekend as the Title Sponsor of the 2025 U.S. Polo Assn. Pacific Coast Open, held August 15-31 at the iconic Santa Barbara Polo & Racquet Club. This prestigious tournament, known as the crown jewel of West Coast polo, brought together top-tier talent and record-breaking crowds for one of the sport's most celebrated events.U.S. Polo Assn. Pacific Coast Open Photo Credit: Michelle Lauren For the first time, U.S. Polo Assn. served as the Title Sponsor of the 2025 U.S. Polo Assn. Pacific Coast Open, one of the oldest and most revered polo tournaments in the world, dating back to 1908. As part of a broader partnership, U.S. Polo Assn. also served as the Official Apparel Brand and Stadium Sponsor
Clean Air Metals Confirms Potential Major Extension at Escape Deposit Along 2.5 km Magnetic Trend4.9.2025 13:00:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / September 4, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to report that it has intersected over 50 m of magmatic sulphide mineralization in the Escape ultramafic conduit at a depth of 400 m (Image 1). The intersection was observed in core from drill hole EL25-001, located approximately 350 m from the current limits of the Escape Deposit ("Escape"). The target was the first of several coincident magnetic and electromagnetic anomalies to be drilled in the eastern half of the Escape conduit. The new intersection opens up 2.5 km of prospective geophysical targets and provides a critical new opportunity to expand the existing mineral inventory1 in the Thunder Bay North ("TBN") project, which compliments the Company's focus on advancing the project to potentially become a significant critical minerals producer of Cu, Pt, Pd and Ni. Assay results are expected to be available in the coming we
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom